Pentavalent antimonial-induced torsade de pointes.
Unexplained sudden deaths following use of pentavalent antimonial drugs have been described, presumably owing to ventricular arrhythmias. A patient is reported with QT interval prolongation and syncopal episodes related to torsade de pointes following treatment of visceral leishmaniasis with meglumine antimoniate. This is the first reported case of documented torsade de pointes following treatment with pentavalent antimonial drugs.
Ortega-Carnicer
J
J
Intensive Care Unit, Hospital Alarcos, Ciudad Real, Spain.
Alcázar
R
R
De la Torre
M
M
Benezet
J
J
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000965:Antimony / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D008297:Male; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony